Health Trials

About this trial

Primary objective of this study is to identify and describe the clinico-biological and molecular characteristics of tumors with somatic POLE (Polymerase ɛ)/POLD1 mutation identified by molecular biology platforms for all stages and primary sites combined

Eligibility criteria

Qualifiers

Any tumor presenting a variant of the exonuclease domain of POLE (exons 9 to 14) classified as pathogenic by the project working group, including: the 4 hotspots of mutations described (codons 286 (P286R/H/L), 411 (V411L), 459 (S459F), 424 (L424/V/I), (2).

Any tumor presenting a variant of the exonuclease domain of PolD1 (exons 8-12), classified as pathogenic by the project working group, including : C319Y(10).

Disqualifiers

Tumor without POLE or POLD1 mutation

Tumor with POLE mutation identified in research studies retrospective research

Opposition of the patient to the registration of his data in the cohort

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

1
CHU -hopital Rangeuil31059, Toulouse France

Sponsors and collaborators

Federation Francophone de Cancerologie Digestive

Lead sponsor

Source ClinicalTrials.gov